

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Primaeva Medical, Inc.	10/14/2009
RECEIVING PARTY DATA	
Name:	Syneron Medical Ltd.
Street Address:	Tavor Building, P.O. Box 550
City:	Yokneam Illit
State/Country:	ISRAEL
Postal Code:	20692
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13418142
CORRESPONDENCE DATA	
Fax Number:	(650)284-2180
Phone:	6502424210
Email:	kmoore@lbhip.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Levine Bagade Han LLP
Address Line 1:	2400 GENG ROAD
Address Line 2:	Suite 120
Address Line 4:	Palo Alto, CALIFORNIA 94303
ATTORNEY DOCKET NUMBER:	PRMV-N-Z004.01-US
NAME OF SUBMITTER:	Sanjay S. Bagade
Total Attachments: 76 source=PRMVNZ00401_20120522_signed_assignment_prmv_syneron#page1.tif source=PRMVNZ00401_20120522_signed_assignment_prmv_syneron#page2.tif source=PRMVNZ00401_20120522_signed_assignment_prmv_syneron#page3.tif	

OP \$40.00 13418142

[illegible]

source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page59.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page60.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page61.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page62.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page63.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page64.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page65.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page66.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page67.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page68.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page69.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page70.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page71.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page72.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page73.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page74.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page75.tif
source=PRMVNZ00401_20120522_signed_assignment_pmv_syneron#page76.tif

AGREEMENT AND PLAN OF MERGER

by and among

SYNERON MEDICAL LTD.,

REVIVE HOLDING SUB INC.,

and

PRIMAEVA MEDICAL, INC.,

and,

WITH RESPECT TO ARTICLES VIII AND X ONLY,

FRAZIER HEALTHCARE V, LP

AS SECURITYHOLDER REPRESENTATIVE

and

U.S. BANK NATIONAL ASSOCIATION

AS ESCROW AGENT AND PAYING AGENT

Dated as of October 14, 2009

TABLE OF CONTENTS

ARTICLE I DEFINITIONS AND INTERPRETATIONS	2
1.1 Certain Definitions	2
1.2 Certain Interpretations	10
ARTICLE II THE MERGER	11
2.1 The Merger	11
2.2 The Closing	11
2.3 The Effective Time	11
2.4 Effect of the Merger	11
2.5 Constituent Documents of the Surviving Company	11
2.6 Directors and Officers	12

REDACTED

ARTICLE III REPRESENTATIONS AND WARRANTIES OF PRIMAIEVA	20
---	----

REDACTED

REDACTED

3.18 Intellectual Property Matters..... 33

REDACTED

ARTICLE IV

REDACTED

REDACTED

ARTICLE V

REDACTED

REDACTED

ARTICLE VI

REDACTED

REDACTED

REDACTED

ARTICLE VII REDACTED

REDACTED

ARTICLE VIII REDACTED

REDACTED

ARTICLE IX REDACTED

REDACTED

ARTICLE X GENERAL PROVISIONS..... 62

REDACTED


10.2	Amendment	64
10.3	Extension; Waiver	64
10.4	Severability	64
10.5	Entire Agreement	64
10.6	Assignment	64
10.7	Failure or Indulgence Not Waiver; Remedies Cumulative.....	65
10.8	Governing Law	65
10.9	Consent to Jurisdiction.....	65

10.10 Waiver of Jury Trial..... 65


10.11 Specific Performance 65

10.12 Counterparts..... 65

SCHEDULES



Section 3.18 – Intellectual Property Matters



AGREEMENT AND PLAN OF MERGER

THIS AGREEMENT AND PLAN OF MERGER (this "Agreement") is made and entered into as of October 14, 2009 by and among Syneron Medical Ltd., an Israeli corporation ("Syneron"), Revive Holding Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Syneron ("Merger Sub"), Primaeva Medical, Inc., a Delaware corporation ("Primaeva"), and, with respect to Articles VIII and X only, Frazier Healthcare V, LP, as the Securityholder Representative, and U.S. Bank National Association, a national banking association, as Escrow Agent and Paying Agent.

WITNESSETH:

WHEREAS, each of the respective Boards of Directors of Syneron, Merger Sub and Primaeva have approved this Agreement and the transactions contemplated hereby, and deems it advisable and in the best interest of their stockholders to enter into this Agreement and consummate the transactions contemplated hereby, pursuant to which, among other things, at the Effective Time, Merger Sub will be merged with and into Primaeva (the "Merger") in accordance with the terms and conditions of this Agreement and the applicable provisions of Delaware Law, Primaeva will continue as the surviving corporation of the Merger and as an indirect wholly owned subsidiary of Syneron and each share of Primaeva Capital Stock outstanding immediately prior to the Effective Time will be cancelled and converted into the right to receive the consideration set forth herein, all upon the terms and subject to the conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and the representations, warranties, covenants and agreements set forth herein, as well as other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, Syneron, Merger Sub and Primaeva hereby agree as follows:

ARTICLE I

DEFINITIONS AND INTERPRETATIONS

1.1 Certain Definitions. For all purposes of and under this Agreement, the following capitalized terms shall have the following respective meanings:

(a) "Acquisition Proposal" shall mean any offer or proposal (other than an offer or proposal by the other party hereto) relating to any Acquisition Transaction.

(b) "Acquisition Transaction" shall mean any transaction or series of related transactions (other than the transactions contemplated by this Agreement or expressly permitted by Section 5.2) involving: (i) a merger or consolidation of Primaeva in which its shareholders do not retain a majority of the voting power in the surviving corporation, (ii) a sale of all or substantially all Primaeva's shares or assets, (iii) declaration or payment by Primaeva of a dividend in excess of fifty percent (50%) of the value of the assets of Primaeva; or (iv) transfer or grant by Primaeva of a worldwide, perpetual exclusive license over all or substantially all of the Primaeva Intellectual Property Rights.

(c) "Affiliate" shall mean, with respect to any Person, any other Person which directly or indirectly controls, is controlled by or is under common control with such Person. For purposes of the immediately preceding sentence, the term "control" (including, with correlative meanings, the terms "controlling," "controlled by" and "under common control with"), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

REDACTED

(e) "Business Day" shall mean any day, other than a Saturday, Sunday and any day which is a legal holiday under the laws of the State of California or is a day on which banking institutions located in such State is authorized or required by Legal Requirements or other governmental action to close.

(f) "Code" shall mean the Internal Revenue Code of 1986, as amended.

(g) "Contract" shall mean any contract, subcontract, note, bond, mortgage, indenture, lease, license, sublicense or other legally binding agreement, commitment, obligation, arrangement or understanding, whether oral or in writing.

(h) "Core Technology" shall mean:

REDACTED

Alternatively, "Core Technology" shall also mean any product that is covered entirely or partially by one or more allowed or issued claims of any Primaeva Patent.

(i) "Delaware Law" shall mean the General Corporation Law of the State of Delaware (the "DGCL") and any other applicable Legal Requirements of the State of Delaware.

(j) "Employee" shall mean all Persons employed by Primaeva or its Subsidiaries on a full or part-time basis, whether on active status or on leaves of absence.

REDACTED

(m) "ERISA" shall mean the Employee Retirement Income Security Act of 1974, as amended, and the rules and regulations promulgated thereunder, or any successor statute, rules and regulations thereto.

(n) "ERISA Affiliate" shall mean any entity which is, or at any applicable time was, a member of (i) a controlled group of corporations (as defined in Section 414(b) of the Code), (ii) a group of trades or businesses under common control (as defined in Section 414(c) of the Code) or (iii) an affiliated service group (as defined under Section 414(m) of the Code or the regulations under Section 414(o) of the Code), any of which includes or included Primaeva, or a Subsidiary of Primaeva, as applicable.

REDACTED

(p) "GAAP" shall mean generally accepted accounting principles, as applied in the United States.

(q) "Governmental Authority" shall mean any government, any governmental or regulatory entity or body, department, commission, board, agency or instrumentality, and any court, tribunal or judicial body, in each case whether federal, state, county, provincial, and whether local or foreign.

REDACTED

(w) "Intellectual Property Rights" shall mean common law and statutory rights anywhere in the world arising under or associated with (i) patents, patent applications and inventors' certificates and divisions, continuations, renewals, reissuances and extensions of the foregoing (as applicable) ("Patent"), (ii) copyrights, copyright registrations and copyright applications, "moral" rights and mask work rights ("Copyrights"), (iii) trade and industrial secrets and confidential information and know how ("Trade Secrets"), (iv) trademarks, trade names and service marks, and any applications or registration of the same ("Trademarks"), (v) domain names and Internet addresses (vi) other proprietary rights relating or with respect to the protection of Technology, and (vii) and any moral rights, rights of attribution or rights to integrity of works.

REDACTED

REDACTED

(oo) "Primaeva Board" shall mean the Board of Directors of Primaeva.

(pp) "Primaeva Bylaws" shall mean the Bylaws of Primaeva, as amended and in effect on the date hereof and as of the Closing Date.

(qq) "Primaeva Capital Stock" shall mean Primaeva Common Stock and Primaeva Preferred Stock.

(rr) "Primaeva Certificate of Incorporation" shall mean the Restated Certificate of Incorporation of Primaeva, as amended and in effect on the date hereof and as of the Closing Date.

(ss) "Primaeva Common Stock" shall mean the Common Stock, par value \$0.0001 per share, of Primaeva.

REDACTED

(bbb) "Primaeva Product" shall mean all products, technologies and services developed (including products, technologies and services under development), owned, made, provided, distributed, sold or licensed by or on behalf of Primaeva.

REDACTED

REDACTED

REDACTED

(vvv) "Syneron Board" shall mean the Board of Directors of Syneron.

REDACTED

REDACTED

ARTICLE II

THE MERGER

2.1 The Merger. Upon the terms and subject to the conditions set forth in this Agreement and the applicable provisions of Delaware Law, at the Effective Time, Merger Sub shall be merged with and into Primaeva, the separate corporate existence of Merger Sub shall thereupon cease and Primaeva shall continue as the surviving entity of the Merger. Primaeva, as the surviving entity of the Merger, is sometimes referred to herein as the "Surviving Company."

2.2 The Closing. The closing of the Merger (the "Closing") shall take place at such location, date and time to be agreed upon by Syneron and Primaeva, which date shall be no later than the second (2nd) Business Day after the satisfaction or waiver (to the extent permitted hereunder) of the last to be satisfied or waived of the conditions set forth in Article VII (other than those conditions that by their terms are to be satisfied at the Closing, but subject to the satisfaction or waiver (to the extent permitted hereunder), of such conditions), or at such other date and time as Syneron and Primaeva shall mutually agree upon in writing. The date upon which the Closing actually occurs pursuant hereto is referred to herein as the "Closing Date."

2.3 The Effective Time. Upon the terms and subject to the conditions set forth in this Agreement, on the Closing Date, Syneron and Primaeva shall cause the Merger to be consummated under the DGCL by filing a certificate of merger in customary form and substance (the "Certificate of Merger") with the Secretary of State of the State of Delaware (the "Delaware Secretary of State") in accordance with the applicable provisions of Delaware Law. The time of such filing and acceptance by the Delaware Secretary of State, or such later time as may be agreed in writing by Syneron and Primaeva and specified in the Certificate of Merger is referred to herein as the "Effective Time."

2.4 Effect of the Merger. At the Effective Time, the effect of the Merger shall be as provided in this Agreement, the Certificate of Merger and the applicable provisions of Delaware Law. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all the property, rights, privileges, powers and franchises of Primaeva and Merger Sub shall vest in Primaeva as the Surviving Company, and all debts, liabilities and duties of Primaeva and Merger Sub shall become the debts, liabilities and duties of Primaeva as the Surviving Company.

2.5 Constituent Documents of the Surviving Company

(a) Certificate of Incorporation of the Surviving Company. Unless otherwise determined by Syneron prior to the Effective Time, the certificate of incorporation of Merger

Sub as in effect immediately prior to the Effective Time shall be the certificate of incorporation of the Surviving Company until thereafter amended in accordance with Delaware Law and as provided in such certificate of incorporation; *provided, however*, that at the Effective Time, Article I of the certificate of incorporation of the Surviving Company shall be amended and restated in its entirety to read as follows: "The name of this corporation is Primaeva Corporation."

2.6 Directors and Officers. At the Effective Time, the directors and officers of the Surviving Company shall be the directors and officers of Merger Sub immediately prior to the Effective Time, each to hold office until their respective successors are duly elected or appointed and qualified.

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

3.18 Intellectual Property Matters.

(a) Section 3.18(a)-1 of the Primaeva Disclosure Schedule contains a complete and accurate list of all Registered Intellectual Property that is a Primaeva Intellectual Property Right, including the patent number or application serial number for each jurisdiction in which such patent or patent application is filed, date issued and filed, and present status thereof (collectively the "Primaeva Registered Intellectual Property"). Section 3.18(a)-2 of the Primaeva Disclosure Schedule contains a complete and accurate list of all Trademarks that are a Primaeva Intellectual Property Right, including the application serial number or registration number, country, province or state, and class of goods covered, as well as a list of all material common law trademarks, tradenames, service marks and service names used by Primaeva. To Primaeva's Knowledge, all Primaeva Intellectual Property Rights are valid and enforceable, and to Primaeva's Knowledge, all Primaeva Intellectual Property Rights which are issued by or registered with, as applicable, the United States Patent and Trademark Office, the United States Copyright Office or in any similar office or agency anywhere in the world are currently in compliance with formal legal requirements (including without limitation, as applicable, payment of filing, examination and maintenance fees, proofs of working or use, timely post-registration filing of affidavits of use and incontestability and renewal applications).

(b) Except as set forth in Section 3.18(b) of the Primaeva Disclosure Schedule, Primaeva exclusively owns or possesses adequate and enforceable rights to use, without payment to a third party, all of the Primaeva Intellectual Property Rights and all other Intellectual Property Rights used by Primaeva, free and clear of any Liens. Primaeva has not transferred ownership of, granted an option to obtain ownership of, or granted an exclusive license to, any third party, of any Primaeva Intellectual Property Rights.

(c) To Primaeva's Knowledge, Primaeva has not, in the conduct of the business of Primaeva, infringed upon, violated or used without authorization, any Intellectual Property Rights owned by any third Person. To Primaeva's Knowledge, the conduct of the business of Primaeva, and the manufacture, sale and/or use of Primaeva's Products, has not and does not infringe, misappropriate or violate any Intellectual Property Rights owned by any third Person. There is no pending or, to Primaeva's Knowledge, threatened (and at no time has there been pending any) suit, arbitration or other adversarial proceeding before any court, government agency or arbitral tribunal, or in any jurisdiction, against Primaeva or its employees, alleging that any activities or conduct of Primaeva's business, or the manufacture, sale and/or use of any of

Primaeva's Products, has infringed, infringes or will infringe upon, violate or constitute the unauthorized use of the Intellectual Property Rights of any third Person, or challenging the ownership, validity, enforceability, or registerability of any Primaeva Intellectual Property Rights. Primaeva is not party to any settlements, covenants not to sue, consents, decrees, stipulations, judgments, or orders resulting from suits, actions or similar legal proceedings, which (i) materially restrict Primaeva's rights to use, license or transfer any Primaeva Intellectual Property Rights, including without limitation, making, selling, licensing, leasing, marketing, distributing or providing any Primaeva Product, (ii) materially restrict the conduct of the business of Primaeva in order to accommodate any third party's Intellectual Property Rights, or (iii) compel or require Primaeva to license or transfer any Primaeva Intellectual Property Rights.

(d) Section 3.18(d) of the Primaeva Disclosure Schedule contains a complete and accurate list of all industry associations, standard setting organizations and similar bodies in which Primaeva is a member, participates or is otherwise involved, or that may otherwise require Primaeva to license any Primaeva Intellectual Property Rights to any third Person. Primaeva has not committed, agreed or become obligated to license on a royalty free basis, any Primaeva Intellectual Property Rights to any third Person as a result of any participation in an industry association, standard setting organization or similar body, or otherwise.

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

10.2 Amendment. Subject to applicable Legal Requirements and the other provisions of this Agreement, this Agreement may be amended by the parties hereto by action taken by their respective boards of directors at any time prior to the Effective Time by execution of an instrument in writing signed on behalf of each of Syneron, Merger Sub and Primaeva; *provided, however*, that, after the adoption of this Agreement by the Primaeva Stockholders, no amendment may be made to this Agreement that requires further approval by such stockholders under applicable Legal Requirements.

10.3 Extension; Waiver. At any time and from time to time prior to the Effective Time, any party or parties hereto may, to the extent legally allowed and except as otherwise set forth herein, (a) extend the time for the performance of any of the obligations or other acts of the other party or parties hereto, as applicable, (b) waive any inaccuracies in the representations and warranties made to such party or parties hereto contained herein or in any document delivered pursuant hereto and (c) waive compliance with any of the agreements or conditions for the benefit of such party or parties hereto contained herein. Any agreement on the part of a party or parties hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party or parties, as applicable. Any delay in exercising any right under this Agreement shall not constitute a waiver of such right.

10.4 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Legal Requirement, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the fullest extent possible.

10.5 Entire Agreement. This Agreement (including the documents and instruments referred to herein, including the Confidentiality Agreement) constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof.

10.6 Assignment. This Agreement shall not be assigned by operation of law or otherwise, except that following the Effective Time Syneron and Merger Sub may assign all or any of their rights hereunder to any wholly owned subsidiary thereof; *provided, however*, that no such assignment pursuant to this Section 10.6 shall relieve Syneron of any of its obligations hereunder.

10.7 Failure or Indulgence Not Waiver; Remedies Cumulative. No failure or delay on the part of any party hereto in the exercise of any right hereunder shall impair such right or be construed to be a waiver of, or acquiescence in, any breach of any representation, warranty or agreement herein, nor shall any single or partial exercise of any such right preclude any other or further exercise thereof or of any other right. All rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available.

10.8 Governing Law. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York, without regard to the conflict of law provisions thereof.

10.9 Consent to Jurisdiction. Each of the parties hereto irrevocably consents to the exclusive jurisdiction and venue of any state court located within the State of California in connection with any matter based upon or arising out of this Agreement or the transactions contemplated hereby, agrees that process may be served upon them in any manner authorized by the laws of the State of California for such persons and waives and covenants not to assert or plead any objection which they might otherwise have to such jurisdiction, venue and process. Each party hereto hereby agrees not to commence any legal proceedings relating to or arising out of this Agreement or the transactions contemplated hereby in any jurisdiction or courts other than as provided herein.

10.10 Waiver of Jury Trial. EACH OF SYNERON, MERGER SUB AND PRIMAIEVA HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HERBY OR THE ACTIONS OF SYNERON, MERGER SUB OR PRIMAIEVA IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT.

10.11 Specific Performance. The parties agree that irreparable damage would occur and that the parties would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which they are entitled at law or in equity.

10.12 Counterparts. This Agreement may be executed in two or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, Syneron, Merger Sub, Primaeva, Escrow Agent and Securityholder Representative have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

SYNERON MEDICAL LTD.

By: 
Name: Fabian Tenenbaum
Title: CFO

REVIVE HOLDING SUB INC.

By: 
Name: Fabian Tenenbaum
Title: Pres

PRIMAEVA MEDICAL, INC.

By: _____
Name: Bankim Mehta
Title: CEO

ESCROW AGENT

By: _____
Name:
Title:

**SECURITYHOLDER
REPRESENTATIVE**

Frazier Healthcare V, LP
By FHM V, LP, its general partner
By FHM V, LLC, its general partner

By: _____
Name: Trevor Moody
Title: Member

IN WITNESS WHEREOF, Syneron, Merger Sub, Primaeva, Escrow Agent and Securityholder Representative have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized

SYNERON MEDICAL LTD.

By: 
Name: Fabian Tenenbaum
Title: CFO

REVIVE HOLDING SUB INC.

By: 
Name: Fabian Tenenbaum
Title: Pres

PRIMAEVA MEDICAL, INC.

By: _____
Name: Bankim Mehta
Title: CEO

ESCROW AGENT

By: _____
Name: _____
Title: _____

**SECURITYHOLDER
REPRESENTATIVE**

Frazier Healthcare V, LP
By FHM V, LP, its general partner
By FHM V, LLC, its general partner

By: _____
Name: Trevor Moody
Title: Member

IN WITNESS WHEREOF, Syneron, Merger Sub, Primaeva, Escrow Agent and Securityholder Representative have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.


SYNERON MEDICAL LTD.

By: _____
Name: Fabian Tenenbaum
Title: CFO

REVIVE HOLDING SUB INC.

By: _____
Name: Fabian Tenenbaum
Title: Pres

PRIMAEVA MEDICAL, INC.

By:  _____
Name: Bankim Mehta
Title: CEO

ESCROW AGENT

By: _____
Name:
Title:

**SECURITYHOLDER
REPRESENTATIVE**

Frazier Healthcare V, LP
By FHM V, LP, its general partner
By FHM V, LLC, its general partner

By: _____
Name: Trevor Moody
Title: Member

IN WITNESS WHEREOF, each of the parties has caused this Agreement to be duly executed and delivered in its name and on its behalf as of the ____ day of October, 2009

SYNERON MEDICAL LTD.

By: _____
Name:
Title:


REVIVE HOLDING SUB INC.

By: _____
Name:
Title:

PRIMAEVA MEDICAL, INC.

By: _____
Name:
Title:

ESCROW AGENT

By: 
Name: **Claude Acoba**
Title: **Vice President**

**SECURITYHOLDERS'
REPRESENTATIVE**

Frazier Healthcare V, LP
By FHM V, LP, its general partner
By FHM V, LLC, its general partner

By: _____
Name: **Trevor Moody**
Title: **Member**

IN WITNESS WHEREOF, Syneron, Merger Sub, Primaeva, Escrow Agent and Securityholder Representative have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.

SYNERON MEDICAL LTD.

By: _____
Name: Fabian Tenenbaum
Title: CFO

REVIVE HOLDING SUB INC.

By: _____
Name: Fabian Tenenbaum
Title: Pres

PRIMAEVA MEDICAL, INC.

By: _____
Name: Bankim Mehta
Title: CEO

ESCROW AGENT

By: _____
Name:
Title:

SECURITYHOLDER
REPRESENTATIVE

Frazier Healthcare V, LP
By FHM V, LP, its general partner
By FHM V, LLC, its general partner

By: _____
Name: Trevor Moody
Title: Member

MATTER	CTRY	TYPE	SERIAL NO	PATENT NO	PUB NO	TITLE	STATUS	FILE DATE	PUBL DATE	ISSUE DATE
PRMV-N-2001-00-US	US	UTL	09/251,554	6,277,119		SYSTEMS AND METHODS FOR SHRINKING COLLAGEN IN THE DERMIS	ISSUED	2/17/1998		8/21/2001
PRMV-N-2002-00-EP	EP	UTL	7873546.7			METHODS AND DEVICES FOR TREATING TISSUE	PENDING	10/10/2007		
PRMV-P-2002-00-US	US	PRV	60/826,607			METHODS AND DEVICES FOR TREATING TISSUE	EXPIRED	10/10/2006		
PRMV-N-2002-00-US	US	UTL	11/076,230		US-2008-0091182-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	2/19/2007	4/17/2008	
PRMV-N-2003-00-US	US	UTL	11/076,235		US-2008-0091183-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	2/19/2007	4/17/2008	
PRMV-N-2004-00-US	US	UTL	11/076,243		US-2008-0091184-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	2/19/2007	4/17/2008	
PRMV-N-2005-00-US	US	UTL	11/076,247		US-2008-0291386-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	2/19/2007	11/13/2008	
PRMV-N-2006-00-US	US	UTL	11/076,251		US-2008-0091185-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	2/19/2007	4/17/2008	
PRMV-N-2002-00-WO	WO	UTL	PCT/US2007/001556		WO 2008/127873	METHODS AND DEVICES FOR TREATING TISSUE	EXPIRED	10/10/2007	10/23/2008	
PRMV-N-2008-00-US	US	UTL	11/784,032		US-2008-0312647-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	6/15/2007	12/18/2008	
PRMV-N-2008-00-WO	WO	UTL	PCT/US2008/006960		WO 2008/157466	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	5/13/2008	12/24/2008	
PRMV-N-2009-00-US	US	UTL	11/832,524		US-2009-0030968-A1	METHODS AND DEVICES FOR TREATING TISSUE	PUBLISHED	8/12/2007	2/5/2009	
PRMV-P-2010-00-US	US	PRV	65/084,303			CARTRIDGE ELECTRODE DEVICE	EXPIRED	10/31/2007		
PRMV-N-2010-00-US	US	UTL	12/024,925		US-2009-0112205-A1	CARTRIDGE ELECTRODE DEVICE	PUBLISHED	2/11/2008	4/30/2009	
PRMV-N-2010-00-WO	WO	UTL	PCT/US2010/002051		WO 2009/050186	CARTRIDGE ELECTRODE DEVICE	PUBLISHED	10/31/2008	5/7/2009	
PRMV-P-2011-00-US	US	PRV	61/013,182			PERCUTANEOUS ENERGY DELIVERY	EXPIRED	12/12/2007		
PRMV-N-2011-00-US	US	UTL	12/055,258		US-2008-0158958-A1	DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PUBLISHED	3/29/2008	6/18/2009	
PRMV-N-2011-00-WO	WO	UTL	PCT/US2009/006589		WO 2009/075996	DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PUBLISHED	12/12/2008	6/18/2009	
PRMV-P-2013-00-US	US	PRV	61/035,936			PRINTED CIRCUIT BOARD MOUNTED SURGICAL ELECTRODES	EXPIRED	3/12/2008		
PRMV-P-2012-00-US	US	PRV	61/080,366			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	EXPIRED	7/14/2008		
PRMV-N-2012-00-US	US	UTL	12/249,773			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	10/10/2008		
PRMV-N-2012-01-US	US	UTL	12/248,760			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	10/10/2008		
PRMV-N-2012-02-US	US	UTL	12/248,807			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	10/10/2008		
PRMV-N-2012-00-WO	WO	UTL	PCT/US2009/005711			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	7/14/2009		
PRMV-P-2012-01-US	US	PRV	61/090,671			BIPOLAR FRACTIONAL LESION	PENDING	9/24/2008		
PRMV-P-2012-03-US	US	PRV	61/104,654			BIPOLAR FRACTIONAL RADIOFREQUENCY TREATMENT AND WOUND HEALING	PENDING	10/10/2008		
PRMV-N-2014-00-US	US	UTL	12/307,448			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	2/6/2009		
PRMV-N-2014-01-US	US	UTL	12/426,706			METHODS FOR APPLYING ENERGY TO TISSUE USING A GRAPHICAL INTERFACE	PENDING	4/20/2009		
PRMV-N-2015-00-US	US	UTL	12/302,936			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	2/25/2009		
PRMV-N-2015-01-US	US	UTL	12/426,747			METHODS FOR APPLYING ENERGY TO TISSUE USING ISOLATED ENERGY SOURCES	PENDING	4/20/2009		
PRMV-N-2015-00-WO	WO	UTL	PCT/US2009/005662			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	7/14/2008		
PRMV-N-2016-00-US	US	UTL	12/396,624			DEVICES AND METHODS FOR PERCUTANEOUS ENERGY DELIVERY	PENDING	8/6/2009		
PRMV-N-2017-00-US	US	UTL	12/412,201			TREATMENT OF SKIN DEFORMATION	PENDING	3/28/2009		
PRMV-N-2018-00-US	US	UTL	12/423,795			CONTROLLED DELIVERY OF THERAPEUTIC ENERGY TO TISSUE	PENDING	4/14/2009		
PRMV-N-2018-00-US	US	UTL				DEVICES AND METHODS FOR LIPOSUCTION	PROPOSED			